Tags

Type your tag names separated by a space and hit enter

Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study.
J Endourol. 2005 Jan-Feb; 19(1):11-4.JE

Abstract

BACKGROUND AND PURPOSE

To assess in a prospective study whether shockwave therapy (SWT) is effective as a first-line treatment for Peyronie's disease.

PATIENTS AND METHODS

Forty patients with previously untreated Peyronie's disease underwent SWT with the Epos overhead-module device (Dornier). The pain severity (visual analog pain scale [VAS] 0-5), the degree of penile angulation after vasoactive drug injection, plaque size by ultrasound measurement, and erectile dysfunction (IIEF score) were assessed prior to and after treatment. Of the 40 patients, 7 underwent two sessions and the rest three sessions. The time interval between treatments was 2 weeks. At a power level of 2 to 5 (mean 4), a maximum of 3000 shockwaves per plaque per treatment were applied. The mean follow-up was 12 months.

RESULTS

All patients completed the protocol. The tolerance and safety were excellent. Of the 25 patients with pain on erection, 12 (48%) noticed relief after the first session, while 9 more were pain free at the end of the treatment (VAS reduction 2.8; P<0.0001, and 2; P<0.001, respectively). For 25 patients (62.5%), an improvement in penile angulation>20 degrees was observed, with a mean reduction of 35 degrees (range 20 degrees-60 degrees) (P<0.001). No significant change in plaque size was noted. Among 28 patients with erectile dysfunction, 18 (64.2%) had a marked increase in erection quality (IIEF score change: +4 for 10 patients, +6 for 4 patients, +8 for 2 patients, +9 for 2 patients).

CONCLUSION

Our results support SWT as an effective and safe first-line treatment for Peyronie's disease.

Authors+Show Affiliations

2nd Department of Urology, Sismanoglio Hospital, University of Athens, Athens, Greece. andskol@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

15735375

Citation

Skolarikos, A, et al. "Shockwave Therapy as First-line Treatment for Peyronie's Disease: a Prospective Study." Journal of Endourology, vol. 19, no. 1, 2005, pp. 11-4.
Skolarikos A, Alargof E, Rigas A, et al. Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. J Endourol. 2005;19(1):11-4.
Skolarikos, A., Alargof, E., Rigas, A., Deliveliotis, C. h., & Konstantinidis, E. (2005). Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. Journal of Endourology, 19(1), 11-4.
Skolarikos A, et al. Shockwave Therapy as First-line Treatment for Peyronie's Disease: a Prospective Study. J Endourol. 2005 Jan-Feb;19(1):11-4. PubMed PMID: 15735375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. AU - Skolarikos,A, AU - Alargof,E, AU - Rigas,A, AU - Deliveliotis,Ch, AU - Konstantinidis,E, PY - 2005/3/1/pubmed PY - 2005/6/10/medline PY - 2005/3/1/entrez SP - 11 EP - 4 JF - Journal of endourology JO - J Endourol VL - 19 IS - 1 N2 - BACKGROUND AND PURPOSE: To assess in a prospective study whether shockwave therapy (SWT) is effective as a first-line treatment for Peyronie's disease. PATIENTS AND METHODS: Forty patients with previously untreated Peyronie's disease underwent SWT with the Epos overhead-module device (Dornier). The pain severity (visual analog pain scale [VAS] 0-5), the degree of penile angulation after vasoactive drug injection, plaque size by ultrasound measurement, and erectile dysfunction (IIEF score) were assessed prior to and after treatment. Of the 40 patients, 7 underwent two sessions and the rest three sessions. The time interval between treatments was 2 weeks. At a power level of 2 to 5 (mean 4), a maximum of 3000 shockwaves per plaque per treatment were applied. The mean follow-up was 12 months. RESULTS: All patients completed the protocol. The tolerance and safety were excellent. Of the 25 patients with pain on erection, 12 (48%) noticed relief after the first session, while 9 more were pain free at the end of the treatment (VAS reduction 2.8; P<0.0001, and 2; P<0.001, respectively). For 25 patients (62.5%), an improvement in penile angulation>20 degrees was observed, with a mean reduction of 35 degrees (range 20 degrees-60 degrees) (P<0.001). No significant change in plaque size was noted. Among 28 patients with erectile dysfunction, 18 (64.2%) had a marked increase in erection quality (IIEF score change: +4 for 10 patients, +6 for 4 patients, +8 for 2 patients, +9 for 2 patients). CONCLUSION: Our results support SWT as an effective and safe first-line treatment for Peyronie's disease. SN - 0892-7790 UR - https://wwww.unboundmedicine.com/medline/citation/15735375/Shockwave_therapy_as_first_line_treatment_for_Peyronie's_disease:_a_prospective_study_ DB - PRIME DP - Unbound Medicine ER -